ABSTRACT

Prostate has remained as the single solid organ for which biopsy cannot be performed from a lesion for decades. Lately, the groundbreaking magnetic resonance imaging (MRI) techniques have emerged to scan prostate cancer and have become an important diagnostic tool in the diagnosis of prostate cancer. Efforts to improve the accuracy of the standard biopsy methods have led to the emergence of target-oriented biopsy methods. Today, MRI-transrectal ultrasound (TRUS) fusion guided biopsy methods are being used increasingly, especially for patients with an increasing prostate specific antigen level after a previous negative biopsy result and for patients under follow-up with active surveillance protocols. Even though it is not yet suggested in guidelines, our view and practice are in line with the fact that MRI-TRUS fusion guided biopsy is the most ideal biopsy method in any patient scheduled for a prostate biopsy with a significant lesion on MRI.